CSI Market
Sign In | Register

Provectus Biopharmaceuticals Inc (PVCT) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access PVCT Annual Cash Flow →
Observing cash flow movements over recent quarters helps explain how Provectus Biopharmaceuticals Inc adapts cash usage as operating conditions change.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-2.29
Depreciation & amortization0.00
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation0.61
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants0.00
Finite Lived Intangible Assets Amortization Expense-
Amortization Of Commitment Fee-
Amortization Of Prepaid Consultant Expense-
Accretion Of United States Treasury Bills-
Loss On Exercise Of Warrants-
Beneficial Conversion Of Convertible Interest-
Convertible Interest-
Compensation Through Issuance Of Stock-
Issuance Of Stock For Services-
Issuance Of Warrants For Services-
Issuance Of Warrants For Contractual Obligations-
Warrant Incentive Expense-
Gain Loss Related To Litigation Settlement-
Noncash Operating Lease Expense0.01
Increase Decrease In Operating Lease Liability-0.01
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Receivables0.00
Increase (Decrease) in Accounts Payable, Trade0.22
Accrued Expense0.64
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-0.10
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net-0.02
Payments for (Proceeds from) Other Operating Activities0.23
Discontinued operations0.00
Net Cash flow from Operating Activities-0.72
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Proceeds from Divestiture of Interest in Consolidated Subsidiaries0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.00
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings1.70
Long-term debt - repayments-0.15
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.08
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Net Proceeds From Loans From Stockholder-
Net Proceeds From Sales Of Preferred Stock And Warrants-
Net Proceeds From Sales Of Common Stock And Warrants-
Proceeds From Exercises Of Warrants And Stock Options-
Cash Paid For Deferred Loan Costs-
Premium Paid On Extinguishments Of Debt-
Proceeds From Issuance Of Common Stock And Warrants-
Proceeds From Issuance Of Convertible Notes Payable Related Parties-
Deposit For Purchase Of Series D1 Preferred Stock-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations0.25
Proceeds From Issuance Of Common Stock Of Majorityowned Subsidiary-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities1.62
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-0.72
Total Cash Flow0.91
4 historic quarters locked

Sign in to unlock the full Provectus Biopharmaceuticals Inc cash flow history.

Sign In Create Free Account

About Provectus Biopharmaceuticals Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q (Period: 20260630)
  • Filed with the SEC: August 13, 2026
  • Source: form10-q.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001493152-26-037671

Figures are derived from filed reports and may be restated. Historical data is subject to revision.